Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 4, 2024. The report discloses updates regarding the clinical development of the Company's product candidates under Regulation FD.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational updates rather than financial performance data.
Material Changes and Operational Updates
- CDI-988: The Company issued a press release providing updates on the clinical development of CDI-988 as a potential treatment for pandemic norovirus and coronavirus.
- CC-42344: The Company provided updates on the clinical development of CC-42344 as a potential treatment for pandemic and seasonal influenza A.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing the specific details of the clinical updates. The text of the 8-K itself does not contain specific forward-looking guidance, quantitative risk factors, or management commentary beyond the announcement of these updates.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for specific clinical trial data and timelines.
- Verify the current status of CDI-988 and CC-42344 in clinical trial registries.
- Check recent financial filings (10-K or 10-Q) for the most recent liquidity and cash burn data, as this 8-K does not contain financial statements.